{"protocolSection":{"identificationModule":{"nctId":"NCT04260347","orgStudyIdInfo":{"id":"0135-0344"},"organization":{"fullName":"Boehringer Ingelheim","class":"INDUSTRY"},"briefTitle":"SITS-IVT in Patients >80 Years Study","officialTitle":"Safe Implementation of Treatments in Stroke (SITS) - Intravenous Thrombolysis in Acute Ischaemic Stroke Patients Over 80 Years, SITS-IVT>80 Years Study","acronym":"SITS_ELDERLY"},"statusModule":{"statusVerifiedDate":"2023-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-05-14","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-12-31","type":"ACTUAL"},"completionDateStruct":{"date":"2022-12-31","type":"ACTUAL"},"studyFirstSubmitDate":"2020-01-31","studyFirstSubmitQcDate":"2020-02-06","studyFirstPostDateStruct":{"date":"2020-02-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-10-13","lastUpdatePostDateStruct":{"date":"2023-10-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Boehringer Ingelheim","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false},"descriptionModule":{"briefSummary":"A non-interventional post-approval study on Safe Implementation of Treatment in Stroke - International Stroke Thrombolysis Register (SITS-ISTR) existing data of intravenous recombinant tissue plasminogen Activator (rt-PA) (0.9 mg/kg) in acute ischaemic stroke patients over 80 years, treated according to the Summary of Product Characteristics (SmPC) in European countries."},"conditionsModule":{"conditions":["Ischaemic Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":1655,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Actilyse® (alteplase) pre-approval","interventionNames":["Drug: Alteplase"]},{"label":"Actilyse® (alteplase) post-approval","interventionNames":["Drug: Alteplase"]}],"interventions":[{"type":"DRUG","name":"Alteplase","description":"Intravenous injection","armGroupLabels":["Actilyse® (alteplase) post-approval","Actilyse® (alteplase) pre-approval"],"otherNames":["Actilyse®"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants with Symptomatic intracerebral haemorrhage (SICH) per Safe Implementation of Thrombolysis - Stroke-Monitoring Study (SITS-MOST) definition","timeFrame":"up to 36 hours"},{"measure":"Mortality (mRS=6) within 90 days","description":"Death within 90 days as classified by the investigator according to cause: cerebral infarct, cerebral haemorrhage, cerebral infarct and haemorrhage unspecified, myocardial infarct, pulmonary embolism, pneumonia, other vascular cause, unknown and other cause of death.","timeFrame":"up to 90 days"},{"measure":"Functional Independency as defined by mRS 0-2 within 90 days","description":"A modified Rankin score, mRS, is used to evaluate daily activity of the patient at day 90. The scores are entered in the on-line entry form. The score 0-1 is defined as favourable outcome and 0-2 as independence of the patient.","timeFrame":"up to 90 days"}],"secondaryOutcomes":[{"measure":"Patient characteristics at baseline including stroke severity (NIHSS)","description":"Baseline measurement during data collection","timeFrame":"up to 6 years"},{"measure":"Number of Participants with a modified Rankin score (mRS) of 0-1","timeFrame":"up to 90 days"},{"measure":"Number of Participants with Symptomatic intracerebral haemorrhage (SICH) per European Cooperative Acute Stroke Study 2 (ECASS 2) definition","timeFrame":"up to 90 days"},{"measure":"Delays of management 1: Time from onset of symptoms - start of treatment","timeFrame":"up to 4.5 hours"},{"measure":"Delays of management 2: Time from onset of symptoms - door (or as captured in the registry arrival at hospital)","timeFrame":"up to 4.5 hours"},{"measure":"Delays of management 3: Door - needle time","timeFrame":"up to 4.5 hours"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients over 80 years old presenting with acute ischaemic stroke symptoms for which thrombolysis treatment was initiated within 4.5 hours after stroke onset according to SmPC are included.\n* Patients over 80 years who received thrombolysis according to SmPC for acute ischaemic stroke (AIS) within 4.5 hours after stroke onset during the period (approximately 3 years) prior to July 2018 are included.\n\nExclusion Criteria:\n\n* Contraindication(s) to the use of IV thrombolysis per local SmPC.\n* Documentation that the patient was enrolled or is planned to be enrolled in an investigational clinical trial at the time of the onset of index event and for the duration of the data collection.","healthyVolunteers":false,"sex":"ALL","minimumAge":"80 Years","stdAges":["OLDER_ADULT"],"studyPopulation":"Patients over 80 years old presenting with acute ischaemic stroke (AIS) symptoms for which thrombolysis treatment was initiated within 4.5 hours after stroke onset according to the SmPC.","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Karolinska University Hospital","city":"Stockholm","zip":"171 76","country":"Sweden","geoPoint":{"lat":59.33258,"lon":18.0649}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Related Info","url":"https://www.mystudywindow.com"}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).\n\nFor more details refer to: https://www.mystudywindow.com/msw/datatransparency"}},"annotationSection":{"annotationModule":{"unpostedAnnotation":{"unpostedResponsibleParty":"Boehringer Ingelheim","unpostedEvents":[{"type":"RELEASE","date":"2023-12-18"},{"type":"UNRELEASE","date":"2023-12-18"}]}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"estimatedResultsFirstSubmitDate":"2023-12-18","submissionInfos":[{"releaseDate":"2023-12-18","unreleaseDate":"2023-12-18"},{"releaseDate":"2023-12-22"}]}},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000010959","term":"Tissue Plasminogen Activator"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"Patient Reported Outcomes","relevance":"HIGH"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}